Oncotarget

Research Papers:

Inhibition of tumor growth by a newly-identified activator for epidermal fatty acid binding protein

Enyu Rao, Puja Singh, Xiuhong Zhai, Yan Li, Ganqian Zhu, Yuwen Zhang, Jiaqing Hao, Young-In Chi, Rhoderick E. Brown, Margot P. Cleary and Bing Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:7815-7827. https://doi.org/10.18632/oncotarget.3485

Metrics: PDF 1043 views  |   HTML 1525 views  |   ?  


Abstract

Enyu Rao1, Puja Singh1, Xiuhong Zhai1, Yan Li1, Ganqian Zhu1, Yuwen Zhang1, Jiaqing Hao1, Young-In Chi1, Rhoderick E. Brown1, Margot P. Cleary1 and Bing Li1

1 The Hormel Institute, University of Minnesota, Austin, MN, USA

Correspondence to:

Bing Li, email:

Keywords: E-FABP, tumor associated macrophages, interferon β, tumor treatment

Received: November 20, 2015 Accepted: February 04, 2015 Published: March 08, 2015

Abstract

Our previous studies have demonstrated that expression of epidermal fatty acid binding protein (E-FABP) in tumor associated macrophages (TAMs) promotes macrophage anti-tumor activity by enhancing IFNβ responses in tumor models. Thus, E-FABP represents a new protective factor in enhancing tumor immune surveillance against tumor development. Herein, we report the compound 5-(benzylamino)-2-(3-methylphenyl)-1,3-oxazole-4-carbonitrile (designated EI-05) as a novel E-FABP activator for inhibition of mammary tumor growth. EI-05 was selected from the ZINC compound library using molecular docking analysis based on the crystal structure of E-FABP. Although EI-05 is unable to bind E-FABP directly, it significantly increases E-FABP expression in macrophages during inflammation. Stimulation of macrophages with EI-05 remarkably enhances lipid droplet formation and IFNβ production, which further promotes the anti-tumor activity of macrophages. Importantly, administering EI-05 in vivo significantly inhibits mammary tumor growth in a syngeneic mouse model. Altogether, these results suggest that EI-05 may represent a promising drug candidate for anti-tumor treatment through enhancing E-FABP activity and IFNβ responses in macrophages.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3485